Welcome to our dedicated page for Thermogenesis Holdings news (Ticker: THMO), a resource for investors and traders seeking the latest updates and insights on Thermogenesis Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Thermogenesis Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Thermogenesis Holdings's position in the market.
ThermoGenesis Holdings, Inc. (THMO) announced a delay in its second quarter earnings release, originally scheduled for August 12, 2020. The new date for the release is set for August 14, 2020, after market close. Following this, a conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET. This delay comes as ThermoGenesis continues to focus on its automated technologies for CAR-T therapies and other cell-based treatments.
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) will release its financial results for the second quarter ended June 30, 2020, and provide a corporate strategic update on August 12, 2020, after market close. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET. Investors can participate by dialing domestic and international numbers or access a live webcast. The company specializes in automated technologies for CAR-T and cell-based therapies, focusing on solutions for clinical biobanking and immuno-oncology.
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) announced that Corning Incorporated's Life Sciences Division has begun distributing its X-SERIES® cell processing platform, enhancing its market reach. The X-SERIES systems are designed for fast, sterile, and automated processing of human blood to isolate immune cells for CAR-T therapies. The platform responds to the growing demand for personalized immunotherapies, featuring systems such as X-LAB® and X-WASH®. ThermoGenesis aims to improve accessibility to these technologies for researchers and clinicians globally, aligning with increased global interest in immunotherapy.
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) will join the Russell Microcap Index following the annual reconstitution, effective June 29, 2020. This inclusion signifies the company’s improved financial and operational performance over the past year. The Russell Microcap Index is key for institutional investors, with approximately $9 trillion in assets benchmarked against it. CEO Chris Xu emphasized that this milestone will enhance visibility within the investment community as ThermoGenesis aims to lead in automated technologies for cell and gene therapy.